Alteration of anti-inflammatory activity of Harpagophytum procumbens (devil's claw) extract after external metabolic activation with S9 mix

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 11, 2014, Pages 1606-1614

  Hostanska, Katarina ^a   Melzer, Joerg ^a   Rostock, Matthias ^a,b   Suter, Andy ^c   Saller, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c Bioforce AG   (Switzerland)

Author keywords

Devil's claw extract; Proinflammatory cytokines; S9 mix; THP 1 cells

Indexed keywords

CAFFEIC ACID; CYTOCHROME P450; CYTOKINE; HARPAGOPHYTUM PROCUMBENS EXTRACT; HARPAGOSIDE; INTERLEUKIN 6; INTERLEUKIN 8; ROSMARINIC ACID; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID; CAFFEIC ACID DERIVATIVE; GLYCOSIDE; LIPOPOLYSACCHARIDE; PLANT EXTRACT; PYRAN DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER; METABOLIC ACTIVATION; NONHUMAN; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PLANT TUBER; RAT; ANIMAL; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HARPAGOPHYTUM; HUMAN; INFLAMMATION; METABOLISM; MONOCYTE; PHYTOTHERAPY;

ACTIVATION, METABOLIC; ANIMALS; ANTI-INFLAMMATORY AGENTS; CAFFEIC ACIDS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOKINES; GLYCOSIDES; HARPAGOPHYTUM; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; LIVER; MONOCYTES; PHYTOTHERAPY; PLANT EXTRACTS; PLANT TUBERS; PYRANS; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84918795720     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12242     Document Type: Article

References (47)

1. Capresse M. Description, identification and therapeutical uses of the devil's claw: Harpagophytum procumbens DC (author's transl). J Pharm Belg 1980; 35: 143-149.
2. Stewart K, Cole D. The commercial harvest of devil's claw (Harpagophytum spp.) in southern Africa: the devil's in the details. J Ethnopharmacol 2005; 100: 225-236.
3. Wegener T. Devil's claw: from African traditional remedy to modern analgesic and antiinflammatory. HerbalGram 2000; 50: 47-54.
4. Chrubasik S et al. A randomized double-blind pilot study comparing Doloteflin® and Vioxx® in the treatment of low back pain. Rheumatology (Oxford) 2003; 42: 141-148.
5. Grant L et al. A review of the biological and potential therapeutic actions of Harpagophytum procumbens. Phytother Res 2007; 21: 199-209.
6. Boje K et al. A new and known iridoid and phenylethanoid glycosides from Harpagophytum procumbens and in vitro inhibition of human leukocyte elastase. Planta Med 2003; 69: 820-825.
7. Inaba K et al. Inhibitory effects of devil's claw (secondary root of Harpagophytum procumbens) extract and harpagoside on cytokine production in mouse macrophages. J Nat Med 2010; 64: 219-222.
8. Speranza L et al. Antiinflammatory effects in THP-1 cells treated with verbascoside. Phytother Res 2010; 24: 1398-1408.
9. Gyurkovska V et al. Anti-inflammatory activity of Devil's claw in vitro systems and their active constituents. Food Chem 2011; 125: 171-179.
10. Shin KM et al. Anti-inflammatory effect of caffeic acid methyl ester and its mode of action through the inhibition of prostaglandin E2, nitric oxide and tumor necrosis factor-alpha production. Biochem Pharmacol 2004; 68: 2327-2336.
11. Clarkson C et al. Identification of major and minor constituents of Harpagophytum procumbens using HPLC-SPE-NMR and HPLC/ESIMS/APCIMS. J Nat Prod 2006; 69: 1280-1288.
12. Loizou S et al. ß-sistosterol exhibits anti-inflammatory activity in human aortic endothelial cells.Mol Nutr Food Res 2010; 54: 551-558.
13. Xagorari A et al. Luteolin inhibits an endotoxin-stimulated phosphoralation cascade and proinflammatory cytokine production in macrophages. J Pharmacol Exp Ther 2001; 296: 181-187.
14. Wang L et al. Distinctive antioxidant and antiinflammatory effects of flavonols. J Agric Food Chem 2006; 54: 9798-9804.
15. Kaszkin M et al. Downregulation of iNOS expression in rat mesangial cells by special extracts of Harpagophytum procumbens derives from harpagosidedependent and independent effects. Phytomedicine 2004; 11: 585-595.
16. Ananuate MC et al. Effect of isolated fractions of Harpagophytum procumbens DC (Devil's Claw) on COX-1, COX-2 activity and nitric oxide production on whole blood assay. Phytother Res 2010; 24: 1365-1369.
17. Jang MH et al. Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929. J Pharmacol Sci 2003; 93: 367-371.
18. Kundu JK et al. Inhibitory effects of the extracts of Sutherlandia frutescens (L.) R. Br. and Harpagophytum procumbens (Devil's Claw). on phorbol ester-induced COX-2 expression in mouse skin: AP-1 and CREB as potential upstream targets. Cancer Lett 2005; 218: 21-31.
19. Loew D et al. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin Pharmacol Ther 2001; 69: 356-364.
20. Huang TH et al. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappa B activation. J Ethnopharmacol 2006; 104: 149-155.
21. Na HK et al. Inhibition of phorbol ester-induced COX-2 expression by some edible African plants. Biofactors 2004; 21: 149-153.
22. Fiebich BL et al. Inhibition of TNFalpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap. Phytomedicine 2001; 8: 28-30.
23. Calixto JB et al. Anti-inflammatory compounds of plant origin. Part II. Modulaton of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 2004; 70: 93-103.
24. Chantre P et al. Efficacy and tolerance of Harpagophytum procumbens versus Diacerhein in treatment of osteoarthritis. Phytomedicine 2000; 7: 177-183.
25. Wegener T, Lupke NP. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC.). Phytother Res 2003; 17: 1165-1172.
26. McLeod DW et al. Investigations of Harpagophytum procumbens (Devil's Claw) in the treatment of experimental inflammation and arthritis in the rat. Br J Pharmacol 1979; 63: 140-141.
27. Whitehouse LW et al. Devil's claw (Harpagophytum procumbens): no evidence for anti-inflammatory activity in the treatment of arthritic disease. Can Med Assoc J 1983; 129: 249-251.
28. Moussard C et al. A drug used in traditional medicine, harpagophytum procumbens: no evidence for NSAIDlike effect on whole blood eicosanoid production in human. Prostaglandins Leukot Essent Fatty Acids 1992; 46: 283-286.
29. Lanhers MC et al. Anti-inflammatory and analgesic effects of an aqueous extract of Harpagophytum procumbens. Planta Med 1992; 58: 117-123.
30. Soulimani R et al. The role of stomachal digestion on the pharmacological activity of plants extracts, using as an example extracts of Harpagophytum procumbens. Can J Physiol Pharmacol 1994; 72: 1532-1536.
31. Kapoor M et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7: 33-42.
32. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004; 18: 2273-2281.
33. Modorai M et al. The interaction potential of herbal medicinal products: a luminescence-based screening platform assessing effects on cytochrome P450 and its use with devil's claw (Harpagophyti radix) preparations. J Pharm Pharmacol 2011; 63: 429-438.
34. Tucker AN et al. In vitro immunological assays for detection compounds requiring activation. Environ Health Perspect 1982; 13: 123-127.
35. Otto M et al. Development of an in vitro assay for the investigation of metabolism-induced drug hepatotoxicity. Cell Biol Toxicol 2008; 24: 87-99.
36. Huang N et al. Rosmarinic acid in Prunella vulgaris ethanol extract inhibits LPS-induced prostaglandin E2 and nitric oxide in RAW264.7 mouse macrophages. J Agric Food Chem 2009; 57: 10579-10589.
37. Hostanska K et al. Evaluation of cell death caused by triterpene glycosides and phenolic substances from Cimicifuga racemosa extract in human MCF-7 breast cancer cells. Biol Pharm Bull 2004; 27: 1970-1975.
38. Hostanska K et al. Comparison of the growth-inhibitory effect of Hypericum perforatum L. extracts, differing in the concentration of phloroglucinols and flavonoids, on leukaemia cells. J Pharm Pharmacol 2003; 55: 973-980.
39. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32: 451-478. 2003.
40. Lila MA, Raskin I. Health related interactions of phytochemicals. J Food Sci 2005; 70: 20-27.
41. Romiti N et al. Effects of Devil's claw (Harpagophytum procumbens) on the multidrug transporter ABCB1/Pglycoprotein. Phytomedicine 2009; 16: 1095-1100.
42. Tunmann P, Lux R. Zur Kenntnis der Inhaltstoffe aus der Wurzel von Harpagophytum procumbens. Dtsch Apoth Ztg 1962; 192: 1274-1275.
43. Zhang L et al. Effects of ß-glycosidase hydrolyzed products of harpagide and harpagoside on cyclooxygenase-2 (COX-2) in vitro. Bioorg Med Chem 2011; 19: 4882-4886.
44. Tippler B et al. Harpagophytum procumbens DC used in traditional medicine inhibits eicosanoid biosynthesis in human whole blood. Int J Tissue React 1997; 19: 101-102.
45. Bel-Rhlid R et al. Hydrolysis of rosmarinic acid from rosemary extract with esterases and Lactobacillus johnsonii in vitro and in a gastrointestinal model. J Agric Food Chem 2009; 57: 7700-7705.
46. Abdelouahab N, Heard C. Effect of the major glycosides of Harpagophytum procumbens (Devil's Claw) on epidermal cyclooxygenase-2 (COX-2) in vitro. J Nat Prod 2008; 71: 746-749.
47. Schulze-Tanzil G et al. Effect of Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro. Arzneimittelforschung 2004; 45: 213-220.